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ABSTRACT 
 
Introduction: Constipation is one of the most common gastrointestinal complaints in children that 
can lead to many complications. The aim of this study was to compare the efficacy of polyethylene 
glycol powder and polyethylene glycol 40% syrup to treat constipation.  
Original Research Article 
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Materials and Methods: This study was a nonrandomized semi-experimental clinical trial. The 
current study was conducted on 80 patients with constipation, referring to Imam Ali (PBUH) Clinic, 
Shahrekord randomly assigned to two groups of 40 each. Subjects were children under 15 years 
old with functional constipation selected by simple sampling since 2015. Group 1 was treated with 
polyethylene glycol powder and Group 2 was treated with polyethylene glycol 40% syrup for two 
months. During the treatment, the patients were examined five times with 2-week intervals and their 
symptoms consisting of defecation frequency, stool consistency, painful defecation, bloody 
defecation, and stool incontinence were registered in a checklist. Data were analyzed using 
SPSS24.  
Results: The comparison of patients’ total status before and after intervention shows that two 
groups were assessed in the weak level in the polyethylene glycol powder group 28(0.70%) cases 
and syrup group 36(0.90%), while after intervention, polyethylene glycol powder group was 
assessed in the high level 35(87.5%) cases and syrup group 37(92%) cases and most of patients 
after intervention promoted from weak and intermediate level before intervention to High level. 
Conclusion: The findings indicated similar efficacy and treatment response of the PEG powder 
and syrup. However, the PEG syrup can be used instead of its powder because of pleasant taste 
and ease of use. 
 
 
Keywords: Constipation; functional constipation; polyethylene glycol. 
 
1. INTRODUCTION  
 
Constipation is a common problem in childhood 
that hurts children and parents and brings about 
healthcare costs due to development of certain 
symptoms such as delayed defecation, difficulty 
defecating, and fecal incontinence resulting from 
the formation and retention of dense masses of 
stool in the rectum. The total prevalence of 
constipation in childhood varies from 0.7% to 
29.6%. Inorganic causes (functional constipation) 
have been reported to be the most common 
cause of constipation in children. Some children 
with functional constipation show fecal 
incontinence and it is a negative indicator in the 
treatment of these patients [1-3].  
 
Use of laxatives, change in diet, and 
consumption of more liquids are some of the 
non-intrusive approaches to treat constipation in 
children [4]. However, these approaches do not 
ensure successful treatment. Moreover, 
polyethylene glycol (PEG) is the most effective 
laxative with the least amount of side effects that 
can be used for children in the long term [5-7]. 
Physical dependency due to use of PEG has not 
yet been reported [8], and the PEG does not 
cause toxic or systemic effects [9].   
 
PEG is a chemical compound with many 
molecules that is not metabolized by colon 
bacteria. PEG 3350 without electrolyte is 
available as powder. This substance is tasteless 
and colorless, and can be dissolved in liquids 
such as drinking water and juice. No colon 
metabolism is the PEG's advantage over other 
laxatives that are fermented in the colon. The 
efficacy of the PEG 3350 for constipation in 
children has already been studied [10]. It is 
recommended to start treatment at 1 g/kg dose 
daily that should be moderated once every three 
days to reach 1-2 defecations per day. In 
children with chronic constipation, the mean 
duration of treatment has been reported 3-30 
months. Some studies have reported the 
recovery rate after 1-year treatment to be 60-
90% [11,12].  
 
When oral PEG is prescribed, it causes hydration 
of the colon contents, facilitation of intestinal 
passage, and painless excretion in a linear, 
dose-dependent manner. Therefore, PEG-based 
laxatives can act more effectively to excrete 
completely than rectal drugs. These drugs are 
used for frequent and short-term treatment of 
chronic constipation [13,14,15,16]. Physical 
dependency due to use of PEG has not yet been 
reported, and the PEG does not cause toxic or 
systemic effects.  
 
Currently, PEG powder should be mixed with a 
large amount of water to be used for treating 
functional constipation. However, many children 
cannot tolerate and use it. PEG syrup is more 
acceptable to children than its powder because 
the syrup has a smaller volume. Moreover, 
parents usually administer the PEG powder to 
children at inappropriate doses. Besides that, the 
PEG syrup contains appropriate essence and 
sweetening substances (sucrose) that cause 
children to accept it more easily. As well, they 
can be administered with appropriate and 
uniform doses of the drug and the parents are 
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less likely to administer it at inappropriate     
doses [17].  
 
Because no study has yet been conducted to 
investigate this issue, this study was conducted 
to compare the efficacy of two therapeutic 
regimens, i.e. polyethylene glycol powder and 
polyethylene glycol 40% syrup, so that a more 
appropriate and tolerable regimen can be 
selected to treat chronic idiopathic constipation 
(CIC) in children under 15 years. 
 
2. MATERIALS AND METHODS 
 
This study was a nonrandomized semi-
experimental clinical trial. The subjects were 
patients with functional constipation according to 
the ROME III, under 15 years referring to the 
Imam Ali (PBUH) Clinic, Shahrekord in 2015-
2016. Sampling was done by simple sampling 
and samples were obtained based on formula: 
z1 −
 
 
= 1/96),   d=
μ  μ 
α√ 
  , 
 
n =  
   
α
 
    β
 
  2, Z1 − B = 0.84, D = 0.05,      
n   =    39≅ 40.  
 
143 children formed the study population of 
which 63 children were excluded. Exclusion 
criteria were: having organic constipation, having 
anorectal abnormality or history of anorectal 
surgery, recognizing Rome III criteria catching 
irritable bowel syndrome, and receiving treatment 
during 2 weeks before initiation of constipation 
study. Also, children who had mental retardation 
or metabolic diseases such as hypothyroidism, 
having Hirschsprung's disease or spinal 
anomalies or anorectal pathology, undergoing 
gastric and intestinal surgery, receiving an 
effective treatment on gastric system (Cisapride, 
Erythromycin, Pramide), not following the 
treatment, not tolerating medication. Inclusion 
criteria were: A. Children under 4 years old, at 
least 2 items of following cases for one month: 
Twice stool or less in each week, once or twice 
fecal in a week (after skill to go WC), fecal mass 
found in the patient's rectum, and a history of 
holding stool. B. Children 4-15 years old, at least 
2 items of following cases for 2 months: Twice 
stool or less in each week, once or twice stool 
incontinence in a week (after skilling to go WC), 
stool mass in the patient's rectum,  a history of 
stool in larger diameters, and a history for 
holding stool.  
 
This project was approved in the ethic committee 
by number of 1394091. Rec. skums.ir in 
Shahrekord University of Medical Sciences. Also, 
a written approval of parents were taken. Then, 
necessary explanations about the study 
procedure were given to the parents. Moreover, 
the legal guardians (parents) of the children 
completed and signed informed consent form. 
This study was a single blind nonrandomized 
semi-experimental clinical trial (only practitioner 
physician and parents were aware of classifying 
patients and children were not aware of 
classifying (powder or syrup group and 
prescription had not different and prescribed 
based on tendency of children).  
 
The samples (n: 80) were systematically and 
randomly assigned to two groups as follows: 
Group A: PEG powder and group B: PEG 40% 
syrup. The dose of the drug in both groups was 
determined as 1 g/kg/day. Group A was 
recommended to dissolve 70 g of the PEG 
powder (one pack) in 1 liter of cooled boiled 
water and make a 0.07 g/ml solution (per the 
manufacturer’s instructions). Treatment with the 
solution at 1 g/kg/day (approximately 14 
ml/kg/day) in divided doses was started. The 
drug dosage could be changed according to the 
patient's clinical response.  
 
For group B, a pharmacist dissolved 40 g of PEG 
powder in 100 ml of distilled water and base 
syrup and made a syrup at 0.4 g/ml dose (per the 
manufacturer’s instructions). The syrup base did 
not have any interaction with pharmaceutical 
substances. Moreover, the formulation of the 
PEG 40% syrup did not need heating or 
additives. Treatment of group B was started with 
the PEG 40% syrup (without electrolyte) at 1 
g/kg/day (equal to 2.5 ml/kg/day) divided into 
doses per day. In this group, the drug dosage 
could be changed according to the patient's 
clinical response as well.  
 
The patients in both groups were given        
similar diet-related recommendations. These 
recommendations included intake of fatty foods 
such as fried potato and fast food, banana, 
cooked carrot, white rice, and dairies such as 
cheese, yoghurt, ice cream, and milk less 
frequently. The children were recommended to 
consume low-fat milk and soybean milk 
(applicable to children under two years). Due to 
limiting the use of calcium, we recommended the 
use of other calcium sources such as orange, 
parsley, soybean, seeds, and cabbage.   
 
In addition, the patients were advised to use 
fruits and vegetables such as plums, zucchini, 
 
 
 
 
Kasiri et al.; JPRI, 28(4): 1-8, 2019; Article no.JPRI.50209 
 
 
 
4 
 
Cucurbita pepo, tomato, spinach, apples, grapes, 
peaches, watermelon, cantaloupe, figs, raisins, 
and whole-grain high fiber foods like popcorn, 
whole wheat bread, and cereals. Frequent 
exercise and going to the toilet after meal were 
also recommended. 
 
The patients were systematically followed up 
once every two weeks for two months. In the 
second visit of follow-up, the efficacy, tolerance, 
and potential side effects of the drugs were 
assessed and the decision about the efficacy of 
the administered dose and reconsideration of the 
dosage was made with reference to the 
frequency of defecation, stool consistency, rectal 
bleeding, painful defecation, and fecal 
incontinence. The purpose of the treatment was 
smooth and painless excretion of stool and 
prevention of fecal accumulation in the rectum. 
The dosage was set in a manner to reach 
excretion frequency and stool consistency of 
interest. Each patient was given a form that 
included information about age, gender, and 
weight and a table including excretion frequency 
per week, painful bowel movement, rectal 
bleeding, stool consistency, and the frequency of 
fecal incontinence per month that was completed 
at examinations of the patients.  
 
Data were analyzed using descriptive statistics 
included frequency, percent, mean, standard 
deviation and analytical statistics: t-test, K2, and 
Fisher exact test.  Differences were significant at 
P<0.05.  
 
3. RESULTS 
 
Polyethylene glycol powder group (group A) 
included 18(0.45%) males and 22(0.55%) 
females; syrup consumed group (Group B) 
included 27 (0.67.5%) males and 13 (0.32.5%) 
females.   
 
Mean±standard deviation and range of age in the 
groups A and B were (72.1± 27.9), (15-130) and 
(72.3± 31.4), (26-156), respectively.  The mean± 
standard deviation and range of weight in the 
group A and group B was (20.60.1± 7.51), (8-42) 
and (19.25± 5.93), (13.5-36), respectively. There 
was no significant difference in the both groups 
regarding gender, age, and weight (P>0.05).  
 
There was no a significant relationship between 
two groups before intervention in all variables 
including frequency of stool incontinence, stool 
consistency, fecal incontinence, painful bowel 
movement, rectal bleeding, and frequency of 
defecation in a month except patient’s total 
status (P>0.05). The overall assessment of the 
patient's status in the group A 4 (10%) cases 
(Polyethylene glycol powder group) were in the 
weak level (P<0.05) and in the groups B, syrup 
consumed group was 12 (30%) cases in the 
intermediate level (Table 1).  
 
After intervention, there was no significant 
relationship in the all studied variables in two 
groups (P>0.05) (Table 2). 
 
The comparison of patients’ total status before 
and after intervention showed that the two 
groups, the polyethylene glycol powder group 
28(0.70%) cases and syrup group 36(0.90%) 
cases, assessed in the weak level; while after 
intervention, polyethylene glycol powder and 
syrup groups assessed in the high level 
35(87.5%) cases and syrup group 37(92%) 
cases, respectively and most of patients after 
intervention promoted from the weak and 
intermediate level to the high level (Table 3). 
 
4. DISCUSSION  
 
PEG-based laxatives can act more effectively to 
excrete completely than rectal drugs. These 
drugs are used for frequent and short-term 
treatment of chronic constipation.  
 
Studies have demonstrated that administration of 
PEG, lactulose, and psyllium have led to the best 
outcome and function.  
 
Oral powdered polyethylene glycol at a 
maintenance dose of 0.78 g/kg/day is safe and 
effective for patients younger than 18 months. 
Dose and safety profiles are similar to those 
reported in older children [18]. 
 
Cleveland et al, reported patients treated with 17 
g of PEG powder per day for four days. At 
completion of the treatment, it was observed that 
PEG could lead to improvement of bowel 
movements function and also no significant 
change was seen in CBC, serum biochemicals, 
and urinalyses [19]. 
 
The results in a study show low-volume PEG and 
sennosides. It is much better tolerated, but it had 
less efficacy than the standard PEG dose given 
alone [20].  
 
Klauser et al.'s study conducted on 20       
patients with constipation demonstrated that 
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administration with 60 g of PEG confirmed the 
findings of the previous study [21].  
 
Among the drugs that are prescribed for 
constipation especially in children, willingness to 
use syrups (mainly due to their pleasant taste 
and use of flavors in them) is higher. Studies 
have reported that the patients especially 
children were unwilling to use the PEG powder 
due to its unpleasant taste [22,23]. 
 
Dipalma et al. investigated patients with 
constipation, concluded that administration with 
17 g of PEG per day led to increased bowel 
movement and soft stool consistency. Besides 
that, no side effects were seen compared to 
placebo-administered group. It should be noted 
that in Dipalma et al.'s study, some patients 
administered with the PEG were reported to 
develop diarrhea but the difference from the 
control group was not statistically significant.     
All these cases confirmed the efficacy of        
PEG and that no side effects caused by this   
drug [24]. 
 
Incidence of diarrhea in people under treatment 
with PEG was 2-40%. Moreover, the 
administered dose of PEG correlated directly to 
the severity and acquisition of diarrhea, but 
discontinuing treatment because of severe 
diarrhea due to administration of PEG was not 
reported [25]. 
 
Cinca et al. studied the efficacy of PEG 3350+E 
solution and prucalopride in treatment of 
constipation, 240 patients were selected and 
randomly assigned to two groups of treatment. 
The results demonstrated that PEG 3350+E was 
at least as effective as and generally better 
tolerated than prucalopride as a treatment for 
chronic constipation [26]. Aghapour et al. 
compared the efficacy of PEG and lactulose in 
treating chronic constipation in children, 128 
children were enrolled and randomly assigned to 
two groups of treatment with PEG and lactulose. 
In this study, the PEG solution was found to be 
more effective in treating chronic constipation 
than lactulose [27]. 
 
Saneian and Mostofizadeh compared the 
efficacy of PEG, magnesium hydroxide, and 
lactulose on functional constipation. 75 children 
of 1-6 years of age randomly assigned to three 
groups of PEG, magnesium hydroxide, and 
lactulose. The patients were treated for one 
month with the standard doses of these drugs. 
After the treatment, fewer side effects were seen 
in patients treated with the PEG [28]. 
 
Table 1. Frequency and percent of variables under the study before intervention 
 
Variables  Frequency Polyethylene glycol 
powder group 
frequency (%)  
Syrup group 
frequency (%) 
Total(percent) P-value 
Frequency of 
defecation 
Less than 3 30(75) 37(92.5) 67(93.8) 0.115 
3-5 4(10) 2(5) 6(7.5) 
6-8 5(12.5) 1(2.5) 6(7.5) 
More than 8 1(2.5) 0(0) 1(1.2) 
Stool 
consistency 
Very tight 37(92.5) 38(95) 75(9.8) 1.000 
tight 2(5) 2(5) 4(5) 
horny 1(2.5) 0(0) 1(1.2) 
loose - - - 
Painful bowel 
movement 
No 9(22.5) 5(12.5) 14(17.5) 0.239 
Yes 31(77.5) 35(87.5) 66(82.5) 
Rectal 
bleeding 
No 31(77.5) 25(62.5) 56(70) 0.143 
Yes 9(22.5) 15(37.5) 24((30) 
Frequency of 
defecationin 
one month 
More than 8 7(17.5) 8(20) 15(18.8) 0.889 
6-8 0(0) 0(0) 0(0) 
3-5 1(2.5) 1(2.5) 2(2.5) 
1-2 0(0) 1(2.5) 1(1.2) 
- 32(80) 30(75) 62(77.5) 
Overall 
assessment of 
patient’s 
status 
High 0(0) 0(0) 0(0) 0.025 
Intermediate 12(30) 4(10) 16(20) 
Weak 28(70) 36(90) 64(80) 
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Table 2. Frequency and percent of variables under study after intervention 
 
Variables Frequency Polyethylene glycol 
powder group 
frequency (%) 
Syrup group 
frequency 
(%) 
Total (%) P-value 
Frequency of 
defecation 
Less than 3 0(0) 0 (0) 0(0) 0.696 
3-5 4(10) 3(7.5) 7(8.8) 
6-8 14(35) 11(27.5) 25(31.2) 
More than 8 22(55) 26(65) 48(60) 
Stool 
consistency 
Very tight 0(0) 0(0) 0(0) 0.755 
tight 5(12.5) 6(15) 11(13.8) 
horny 35(87.5) 33(82.5) 68(85) 
loose 0(0) 1(2.5) 1(1.2) 
Painful bowel 
movement 
No 36(90) 38(95) 74(92.5) 0.675 
Yes 4(10) 2(5) 6(7.5) 
Rectal bleeding No 40(100) 40(100) 80(100) - 
Yes 0(0) 0(0) 0((100) 
Frequency of 
defecation in a 
month 
More than 8 0(0) 0(0) 0(0) 0.423 
6-8 1(2.5) 0(0) 1(1..2) 
3-5 1(2.5) 0(0) 1(1.2) 
1-2 2(5) 1(2.5) 3(3.8) 
- 36(90) 39(97.5) 75(93.8) 
Overall 
assessment of 
patient’s status 
High 35(87.5) 37(92.5) 72(90) 0.712 
Intermediate 4(10) 3(7.5) 7(8.8) 
Weak 1(2.5) 0(0) 1(1.20) 
 
Table 3. The comparison groups before and after of total assessment of patient’s status 
 
Assessment 
of patient’s 
status before 
intervention 
Level High 
frequency 
(Percent) 
Intermediate 
frequency(Percent) 
Weak 
frequency(Percent) 
Total 
Polyethylene 
glycol  powder 
group 
High 0(0) 0(0) 0(0) 0(0) 
Intermediate 11(91.7) 1(8.3) 0(0) 12(30) 
Weak 24(85.7) 3(10.7) 1(3.6) 28(70) 
Total 35(87.7) 4(10) 1(2.5) - 
Syrup group 
 
High 0(0) 0(0) 0(0) 0(0) 
Intermediate 4(100) 0(0) 0(0) 4(10) 
Weak 33(91.7) 3(8.3) 0(0) 36(90) 
Total 37(92.5) 3(7.5) 0(0) - 
 
This study shows that the PEG powder and 
syrup are equally effective. However, retention 
and availability of the PEG powder are much 
higher than its syrup. Regarding the PEG 
powder, as with the syrup, no risk or a special 
complication was reported which is an advantage 
of this drug. 
 
One of the limitations of this study was that 
complications of drugs were not studied through 
laboratory tests, and it is suggested to be 
considered in future studies. 
  
5. CONCLUSION  
 
The findings represented similar efficacy of the 
PEG powder and syrup on frequency of 
defecation, fecal consistency, painful bowel 
movement, rectal bleeding, and fecal 
incontinence in the two groups. However, 
retention and availability of the PEG powder are 
easier than its syrup. Moreover, the patients are 
more willing to take the PEG syrup rather than 
the PEG powder because of its more pleasant 
taste, which is a remarkable advantage of the 
PEG powder. 
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